LONDON (Alliance News) - Quantum Pharma PLC on Thursday said it has signed a series of out-licensing deals in Europe for its recently-acquired Lamda division.
Quantum said a generic plus dossier, which includes an undisclosed active pharmaceutical ingredient co-developed by Lamda, has been out-licensed to an unnamed French pharmaceutical company for more than 40 territories. Lamda will receive licence fees and rights to future royalty income under the agreement.
Lamda has also out-licensed a generic dossier for an undisclosed API to another unnamed pharmaceutical company for a fixed licence fee, with a royalty fee over five years once the product is licensed in Germany.
No financial details were disclosed on either agreement.
"At the time of acquisition we stated that part of the upside potential within Lamda was its ability to out-licence products, and these initial two European out-licensing deals demonstrate that," said Andrew Scaife, Quantum's chief executive.
Shares in Quantum were up 1.6% to 127.00 pence on Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
